⌕
Verastem · VSTM · Nasdaq
Tenet 18 · Weak
Compare
$7.70−5.87%At closeTenet 18 · Weak
$7.70−0.48 (−5.87%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Verastem (VSTM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 16, 2026 · 14:13 ETEARNINGS EXPECTED BY FEB 18
Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance

Verastem NASDAQ: VSTM is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent la…

● MarketBeatNov 11, 2026 · 09:13 ET
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path

Verastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile executives said was com…

● MarketBeatNov 10, 2026 · 02:12 ET
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

Verastem NASDAQ: VSTM is advancing its experimental KRAS G12D inhibitor VS-7375 toward potential accelerated approval in pancreatic cancer, with plans to expand studies in colorectal and lung cancers, company executives …

● MarketBeatNov 6, 2026 · 19:15 ETEARNINGS EXPECTED BY FEB 18
What Verastem (VSTM) Said on Its Q3 Earnings Call

Verastem NASDAQ: VSTM reported $24 million in third-quarter 2026 net product revenue as refills of its ovarian cancer treatment offset a moderation in new patient starts. The company also outlined plans to begin a late-s…

● Seeking AlphaNov 6, 2026 · 15:15 ETEARNINGS EXPECTED BY FEB 18
Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript

Verastem, Inc. ( VSTM ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Julissa Viana - Senior Vice President of Corporate Communications, Investor Relations & Patient Advocacy Daniel Paterson - P…

● Zacks Investment ResearchNov 5, 2026 · 18:46 ETEARNINGS EXPECTED BY FEB 18
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $1.35 per share a year ago.…

● Business WireNov 5, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 18
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the thir…

● Business WireNov 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Verastem Oncology to Participate in Upcoming November Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is s…

● Business WireOct 22, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 18
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a …

● Seeking AlphaOct 14, 2026 · 18:54 ET
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript…

● MarketBeatOct 14, 2026 · 12:02 ET
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer a…

● BenzingaOct 14, 2026 · 10:17 ETEARNINGS EXPECTED BY FEB 18
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Oncology (NASDAQ:VSTM) reported encouraging early clinical results for its experimental KRAS G12D inhibitor VS-7375, with the drug demonstrating antitumor activity across pancreatic, colorectal, and lung cancers…

● BarronsOct 14, 2026 · 09:46 ET
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.…

● Business WireOct 14, 2026 · 06:04 ETCOMPANY'S OWN WORDS
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-…

● Business WireOct 14, 2026 · 06:01 ETCOMPANY'S OWN WORDS
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has be…

● Business WireOct 14, 2026 · 06:00 ET
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.…

● Zacks Investment ResearchOct 12, 2026 · 10:56 ETEARNINGS EXPECTED BY FEB 18
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean …

● Seeking AlphaOct 6, 2026 · 04:31 ETEARNINGS EXPECTED BY FEB 18
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 '26 net product revenues reached $25.1M in just the fourth quar…

● Business WireOct 5, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restrict…

● Defense WorldOct 5, 2026 · 08:07 ET
Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They currently have a $18.00 target…

● Defense WorldOct 5, 2026 · 08:06 ET
HC Wainwright Reaffirms “Buy” Rating for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Monday, MarketBeat Ratings reports. They presently have a $18.00 target price on …

● Business WireOct 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.…

● Defense WorldSep 29, 2026 · 06:15 ET
Head to Head Survey: Verastem (NASDAQ:VSTM) & Sangamo Therapeutics (NASDAQ:SGMO)

Verastem (NASDAQ: VSTM - Get Free Report) and Sangamo Therapeutics (NASDAQ: SGMO - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on …

● Business WireSep 28, 2026 · 16:10 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 18
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.…

● Business WireSep 24, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.